Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

IMEXHS LIMITED Capital/Financing Update 2021

Oct 4, 2021

65120_rns_2021-10-04_fac6bcbd-760a-4f4c-9ec1-eafe601e14e0.pdf

Capital/Financing Update

Open in viewer

Opens in your device viewer

5 October 2021

ASX ANNOUNCEMENT

RIMAB Acquisition Completed

IMEXHS Limited (ASX: IME) (“IMEXHS” or “the Company”) is pleased to announce that the acquisition of RIMAB SAS, as announced to the ASX on 26 July 2021, has now completed.

A total of 2,332,172 fully paid ordinary shares, forming part of the consideration for the acquisition, were issued to the sellers on 5 October 2021. These shares will be subject to voluntary escrow for a period of 12 months from their date of issue.

Authorised for release by the board of IMEXHS Limited

-ENDS-

For more information, please contact:

Media and Investor Relations

Vanessa Beresford, Citadel-MAGNUS E: [email protected] T: +61 451 422 892

Business Inquiries

Reena Minhas, CFO & Company Secretary E: [email protected] T: +61 (0)2 9030 0040

About IMEXHS

IMEXHS Limited (ASX: IME) is a leading imaging Software-as-a-Service (SaaS) and ancillary solutions provider with 310 sites and distributors in 15 countries. Founded in 2012, IMEXHS is known for its innovation in the imaging services market, offering flexible and scalable imaging solutions via its AQUILA branded suite of solutions for next generation Picture Archiving and Communications System (PACS) and integrated medical imaging systems (including a Radiology Information System (RIS), a Cardiology Information System (CIS) and an Anatomical Pathology Laboratory Information System (APLIS)). The AQUILA™ system is completely cloudbased, vendor neutral and zero footprint with no need for installed software. The IMEXHS products are designed to increase productivity and save money for end users, with a scalable platform that is configured for the future and enhances patient outcomes. For more information, visit www.imexhs.com